Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans
- 1 September 2004
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 44 (9), 1054-1062
- https://doi.org/10.1177/0091270004268044
Abstract
Simvastatin and fenofibrate are both commonly used lipid‐regulating agents with distinct mechanisms of action, and their coadministration may be an attractive treatment for some patients with dyslipi...Keywords
This publication has 25 references indexed in Scilit:
- Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearanceClinical Pharmacology & Therapeutics, 2003
- MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trialThe Lancet, 2003
- Robotic inhibition assay for determination of HMG-CoA reductase inhibitors in human plasmaJournal of Clinical Laboratory Analysis, 2002
- Cerivastatin and Reports of Fatal RhabdomyolysisNew England Journal of Medicine, 2002
- Effects of liquid chromatography mobile phase buffer contents on the ionization and fragmentation of analytes in liquid chromatographic/ionspray tandem mass spectrometric determinationJournal of Mass Spectrometry, 2002
- Lack of a Clinically Significant Pharmacokinetic Interaction between Fenofibrate and Pravastatin in Healthy VolunteersThe Journal of Clinical Pharmacology, 2000
- Concomitant use of cytochrome P450 3A4 inhibitors and simvastatinThe American Journal of Cardiology, 1999
- Micronised FenofibrateDrugs, 1997
- Clinical Pharmacokinetics and Practical Applications of SimvastatinClinical Pharmacokinetics, 1993
- Regulation of the mevalonate pathwayNature, 1990